MedPath

A CLINICAL STUDY OF RUBRICS OF RINGWORM FROM KNERR REPERTORY

Phase 3
Not yet recruiting
Conditions
Tinea corporis,
Registration Number
CTRI/2023/05/053117
Lead Sponsor
KHUSHALI KUBERBHAI PATEL
Brief Summary

SKIN DISEASES ARE MAJOR HEALTH PROBLEM AFFECTING A HIGH PROPORTION OF POPULATION OF INDIA SKIN DISEASE CAN PLACE A HEAVY EMOTIONAL AND PSYCHOLOGICAL BURDEN ON PATIENTS THAT MAY BE FAR WORSE THAN PHYSICAL IMPACT THE STUDY WILL BE EXPERIMENTAL AND INTERVENTIONAL UNCONTROLLED TRIAL A STUDY WILL BE CONDUCTED WITH 34 SAMPLES AND WHICH WILL BE SELECTED FROM 2 PROJECT SITE ON BASIS OF INCLUSION AND EXCLUSION CRITERIA THROUGH PURPOSIVE SAMPLING CONSENT WILL BE TAKEN OF CHOSEN CASES CASE TAKING WILL BE DONE ACCORDING TO GUIDELINES MENTIONED BY DR HAHNEMANN IN APHORISMS NUMBER 83 TO 104 FURTHER CASE PROCESSING WILL BE DONE USING ZOMEO SOFTWARE OR BOOK FORM OF KNERR REPERTORY TO DIFFERENTIATE GROUP OF MEDICINES HERING GUIDING SYMPTOM OF OUR MATERIA MEDICA WILL BE USED CHOSEN REMEDY WILL BE GIVEN IN  VARIOUS POTENCY AS PER REQUIREMENT OF CASES. THE FOLLOW UP BE TAKEN USING RINGWORM SYMPTOM SCORE AT 7 15 OR 21 DAYS INTERVALAS PER CASE REQUIREMENT  AFTER CESSEATION OF TREATMENT PATIENT WILL BE FOLLOWED UP FOR AT LEAST 3 MONTHS TO CHECK RELAPSE ANALYSIS OF RESULT WILL BE DONE ACCORDING TO RESPONSE OBTAINED AFTER TREATMENT THE PERCENTAGE CRITERIA FOR PARTICULAR CASE WILL BE OBTAINED WITH USE OF RINGWORM SYMPTOM SCORE STATISTICAL ANALYSIS WILL BE DONE WITH PAIRED T-TEST THE EXPECTED RESULT WILL BE EITHER SIGNIFICANT OR NO USEFULNESS OF RUBRICS OF RINGWORM FROM KNERR REPERTORY IN TREATING THE CASES OF RINGWORM

Detailed Description

Not available

Recruitment & Eligibility

Status
Not Yet Recruiting
Sex
All
Target Recruitment
34
Inclusion Criteria

DIAGNOSED CASES OR CASES WITH CLINICAL PRESENTATION OF RINGWORM.

Exclusion Criteria

CASES OF RINGWORM WITH AIDS CASES OF RINGWORM COMPLICATED WITH OTHER SKIN COMPLAINT CASES OF RINGWORM WITH SEVERELY IMMUNOCOMPROMISED STATE CASES OF RINGWORM IN PREGNANT WOMEN.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
RINGWORM SYMPTOM SCOREFOLLOW UP WILL BE TAKEN ON 7 15 21 DAYS AS PER CASE REQUIREMENT
Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

SMT S I PATEL (IPCOWALA) HOMOEOPATHIC HOSPITAL

🇮🇳

Anand, GUJARAT, India

SMT S I PATEL (IPCOWALA) HOMOEOPATHIC HOSPITAL
🇮🇳Anand, GUJARAT, India
DR MEERA SHAH
Principal investigator
9898692003
dr.meerashah@yahoo.com

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.